Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

Study acronym: iPULSAR-CRC
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years 6 months later Mar 1, 2026 → Sep 30, 2029
See other at-risk trials from Fudan University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 1, 2026 to Sep 30, 2029 Show 4 more changesShow less
    • Start date: Mar 1, 2024 to Sep 30, 2024
    • Study completion pushed from Mar 1, 2028 to Sep 30, 2030
    • Secondary endpoints: details revised at 1 of 5 entries
    • Eligibility criteria expanded, about 1 word
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.
Trial Details
NCT Number NCT06841159
Lead Sponsor Fudan University
Conditions
(from sponsor)		 Microsatellite Stable Metastatic Colorectal Cancer
Enrollment 116 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov